



May 28, 2024

Board of Directors

Victor J. Reyes, MBA
Deloitte Consulting LLP
Chair

Donna R. Cryer, JD
President and CEO

Lisa Boyette, MD, PhD
Gilead Sciences Inc.
Treasurer

Brian Munroe
Bausch Health Companies, Inc.
Secretary

Laurie Mobley
BRG Communications
Development Co-Chair

Amy L. Wright, JD
Taft, Stettinius & Hollister
Development Co-Chair

Nicholas Austin, JD
Microsoft Inc.

Shonta Chambers
Patient Advocate Foundation

Dennis R. Cryer, MD, FAHA
CryerHealth LLC

Gary Deverman, CFRE
NutriStyle

Ben Goodman
Maine Dept of Economic &
Community Development

Esther Krofah, MPP
Milken Institute

Melodie Narain-Blackwell
Color of Crohn's & Chronic Illness, Inc.

Lewis R. Roberts, MB, ChB, PhD
Mayo Clinic

Global Liver Institute
4323 Westover Place NW
Washington, DC 20016

✉ info@globalliver.org
🌐 globalliver.com

The Honorable Kathy Hochul
Governor of New York State
NYS State Capitol Building
Albany, NY 12224

Dear Governor Hochul:

I am writing to support Medicaid policies addressing the chronic disease of obesity that are based on sound science and support health equity. Global Liver Institute (GLI) is a nonpartisan nonprofit patient advocacy organization committed to improving the lives of individuals and families impacted by liver disease by promoting innovation, encouraging collaboration, and scaling optimal approaches to help eradicate liver diseases. We are the leading global liver patient advocacy organization representing the over 100 million people in the United States with liver disease, the additional 25,000 men and 11,000 women who get liver cancer each year, and the 19,000 men and 9,000 women who die from it each year.

GLI recognizes the relationship between nonalcoholic fatty liver disease (NAFLD) also known as metabolic dysfunction-associated steatotic liver disease (MASLD), and its advanced form, nonalcoholic steatohepatitis (NASH) also known as metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Preventing liver disease is directly associated with treating and reducing obesity. Worldwide, NASH/MASH affects more than 148 million people and continues to become more prevalent each year. Research has closely linked the presence of NASH/MASH to metabolic comorbidities such as obesity and diabetes.¹ With the expectation that 1 in 4 individuals will be obese by 2035,² it is crucial that we utilize unbiased and science-based approaches to both NASH/MASH and obesity care. GLI stands alongside the obesity advocacy community in recognizing obesity as a serious and complex condition that is a risk factor for developing NASH/MASH.

While we applaud the State of New York for providing access to medication treatment for obesity to NY state employees, we are concerned that the population currently lacking access to the full array of obesity treatments is the state's Medicaid population. The disparity in coverage is stark and contrary to the state's goals for health equity. Currently, New York's budget states, "No payment will be made for any drug which has weight reduction as its sole clinical use." This provision only serves to entrench bias and stigma associated with a condition that is recognized by experts to be a chronic disease – yet is treated by New York's Medicaid program unlike any other chronic disease by refusing access to care. The science does not support New York's current position. Addressing obesity is widely understood to have preventive benefits for fatty liver disease, cardiovascular disease, diabetes, etc. Prevention not only saves lives but would save money and hardship by addressing the personal and financial burden of obesity and related diseases and conditions for so many people and families.

Therefore, we ask that this exclusion be eliminated from the state's budget. Going forward, we hope that the state will not approach the conversation of how to cover new treatments for obesity through

¹ <https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.28431>

² <https://www.worldobesityday.org>

the lens of stigma and bias, and instead approach coverage as it would any other treatable chronic disease affecting millions of Americans.

Please reach out to Jeff McIntyre, GLI Vice President for Liver Health Programs, for additional information at jmcintyre@globalliver.org.

Sincerely,



Donna R. Cryer, JD
President & CEO
Global Liver Institute

cc:

Chairman Gustavo Rivera, Senate Committee on Health
Ranking Member Patrick M. Gällivan, Senate Committee on Health
Chairman David I. Weprin, Assembly Committee on Insurance
Senator Jeremy Cooney
Assemblymember Karines Reyes

About Global Liver Institute

Global Liver Institute (GLI) was built to solve the problems that matter to liver patients, equipping advocates to improve the lives of individuals and families impacted by liver disease. GLI promotes innovation, encourages collaboration, and supports the scaling of optimal approaches to help eradicate liver diseases. GLI believes liver health must take its place on the global public health agenda commensurate with the prevalence and impact of liver illness. GLI is the only patient-created, patient-driven nonprofit organization tackling liver health and all liver disease holistically, operating globally. Follow GLI on [Facebook](#), [Instagram](#), [LinkedIn](#), and [YouTube](#).

